Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280506 | 0.95 | ACHE (0.50) | ACHEMEN1KMT2A | |
| SCHEMBL7274924 | 0.89 | ACHE (0.57) | ACHE | |
| SCHEMBL7281953 | 0.89 | ACHE (0.57) | ACHE | |
| SCHEMBL7274684 | 0.88 | ACHE (0.56) | ACHE | |
| SCHEMBL7274846 | 0.88 | ACHE (0.56) | ACHE | |
| SCHEMBL7273759 | 0.87 | ACHE (0.51) | ACHE | |
| SCHEMBL7271550 | 0.86 | ACHE (0.53) | ACHE | |
| SCHEMBL195472 | 0.86 | ACHE (0.53) | ACHE | |
| SCHEMBL7274681 | 0.85 | ACHE (0.48) | ACHE | |
| SCHEMBL7281640 | 0.84 | ACHE (0.51) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0481429-B1 | Quinoline derivatives | SS PHARMACEUTICAL CO (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-0987262-A1 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-5300517-A | Treating Alzheimer's | SS PHARMACEUTICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5240934-A | Cognition activators | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5190951-A | Inhibitors of acetylcholinesterase, treatment of senile dementia | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0481429-A2 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | ACHE 1/4885MEN1 2903/4885KMT2A 2626/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885MEN1 3293/4885KMT2A 1919/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | ACHE 1/4885MEN1 3760/4885KMT2A 1482/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885MEN1 3303/4885KMT2A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.